CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases
- 1 March 2008
- journal article
- review article
- Published by Elsevier in Kidney International
- Vol. 73 (6) , 684-690
- https://doi.org/10.1038/sj.ki.5002731
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Direct effects of dexamethasone on human podocytesKidney International, 2006
- Mammalian cyclin-dependent kinasesTrends in Biochemical Sciences, 2005
- Dexamethasone Prevents Podocyte Apoptosis Induced by Puromycin AminonucleosideJournal of the American Society of Nephrology, 2005
- Systems biology in drug discoveryNature Biotechnology, 2004
- Pharmacological inhibitors of glycogen synthase kinase 3Trends in Pharmacological Sciences, 2004
- GSK3 inhibitors: development and therapeutic potentialNature Reviews Drug Discovery, 2004
- The glamour and gloom of glycogen synthase kinase-3Trends in Biochemical Sciences, 2004
- Pharmacological inhibitors of cyclin-dependent kinasesTrends in Pharmacological Sciences, 2002
- Cyclophosphamide Therapy in the Nephrotic Syndrome in ChildhoodBMJ, 1969
- TREATMENT OF NEPHROSIS WITH CORTISONE 12Journal of Clinical Investigation, 1950